Incorporating Cystatin C to Predict Methotrexate Elimination in Patients with CNS Lymphoma and Suspicious Renal Function

Case Reports in Hematology
Jason N BarretoErin Frazee

Abstract

High-dose methotrexate (MTX; ≥1 g/m2) is a renally eliminated and nephrotoxic first-line therapy for central nervous system (CNS) lymphoma. Creatinine-based estimation of renal function is the recommended approach to dosing MTX in these cases, but nonrenal determinants of creatinine production and elimination in cancer patients such as malnutrition and cachexia lead to overestimation of glomerular filtration rate (GFR) by this method and a heightened risk for drug toxicity. Serum cystatin C is one of the first readily available, relatively inexpensive, endogenous biomarkers to emerge as a practical adjunct to creatinine for estimation of renal function for drug dosing. In this report, we describe two cases where cystatin C was used in conjunction with creatinine to inform MTX dosing for CNS lymphoma. In both cases, the estimated GFR was nearly 40% lower with the combination of the two biomarkers compared to creatinine-only estimates. Empiric MTX dose reductions as a product of these results likely spared the patients sustained exposure to toxic drug concentrations and facilitated earlier administration of supportive care interventions. Further prospective investigations with validated dosing regimens including cystatin C are wa...Continue Reading

References

Sep 22, 1977·The New England Journal of Medicine·R G StollerB A Chabner
Jan 1, 1976·Nephron·D W Cockcroft, M H Gault
Aug 1, 1996·Scandinavian Journal of Clinical and Laboratory Investigation·O TenstadK Aukland
Mar 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tracy BatchelorRegina Priet
Dec 18, 2004·Critical Reviews in Clinical Laboratory Sciences·Michele Mussap, Mario Plebani
Sep 2, 2008·Neuro-oncology·Jay-Jiguang ZhuTracy T Batchelor
Nov 14, 2008·Current Opinion in Critical Care·Norbert LameireRaymond Vanholder
Jan 3, 2009·Kidney International·Lesley A StevensAndrew S Levey
Dec 15, 2010·Seminars in Nephrology·Mark A Perazella, Gilbert W Moeckel
Aug 20, 2011·Clinical Journal of the American Society of Nephrology : CJASN·Alfonso SegarraAna Sobrado
Nov 7, 2012·Annals of Clinical Biochemistry·Janice S C Chew-HarrisZoltan H Endre
Aug 22, 2013·Blood·James L RubensteinPatrick Treseler
Aug 9, 2016·The Oncologist·Scott C HowardR Donald Harvey
Mar 12, 2017·Scientia pharmaceutica·Nada E HammoudaAmal M El-Gayar

❮ Previous
Next ❯

Citations

Mar 19, 2020·Pharmacy : Journal of Pharmacy, Education and Practice·Hilary R TeafordErin F Barreto

❮ Previous
Next ❯

Methods Mentioned

BETA
urine collection
biopsy
pharmacotherapies

Related Concepts

Related Feeds

Cachexia & Brown Fat

Cachexia is a condition associated with progressive weight loss due to severe illness. In cancer patients, it is proposed to occur as a result of tumor-induced energy wasting. Several proteins have been implicated in browning and depletion of white adipose tissue. Here is the latest research on cachexia and brown fat.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

Cardiac Cachexia

Cardiac cachexia is a syndrome associated with the progressive loss of muscle and fat mass. It most commonly affects patients with heart failure and can significantly decrease the quality of life and survival in these patients. Here is the latest research on cardiac cachexia.